Morgan Stanley, BofA Merrill Lynch, Jefferies & Co.
For IPO Boutique's "scale of 1 to 5" BUY rating on Sagent Pharmaceuticals, and our comprehensive analysis, click the "Buy Market Research" link.
About Sagent Pharmaceuticals (adapted from Sagent Pharmaceuticals prospectus): Sagent Pharmaceuticals is an injectable pharmaceutical company that develops and sources products that are sold primarily in the United States through their sales and marketing team. With a primary focus on generic injectable pharmaceuticals, Sagent currently offers customers a range of products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials, pre-filled, ready-to-use syringes, medical devices and premix bags, and Sagent generally seeks to develop injectable products where the form or packaging of the product can be enhanced to improve delivery, product safety or end-user convenience.
Sagent Pharmaceuticals' management team includes industry veterans who have previously served critical functions at other injectable pharmaceutical companies and have long-standing relationships with customers, regulatory agencies and suppliers.
This description is adapted from Sagent prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus..
Share this IPO Profile:
IPO Boutique aggregates information on public companies and private companies, such as Sagent "SGNT" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.